Lung Cancer

Thyroid Toxicity May Predict Response to Immunotherapy in Metastatic NSCLC

September 22, 2020

The presence of hypothyroidism caused by treatment with immunotherapy correlated with improvement in overall survival among patients with non–small cell lung cancer, suggesting that thyroid toxicity may be a predictor of response to immunotherapy in this patient population.

Survival Improvement Observed with Cemiplimab in Frontline Advanced PD-L1+ NSCLC

September 21, 2020

In the phase 3 EMPOWER-Lung 1 trial, patients with advanced non–small cell lung cancer with PD-L1 expression on at least 50% of their tumor cells, had a significant improvement in overall survival and progression-free survival with cemiplimab-rwlc monotherapy compared with platinum-doublet chemotherapy.

Phase 3 Trial Results Do Not Support PORT in Resected Stage IIIAN2 NSCLC

September 20, 2020

Patients with completely resected stage IIIAN2 non–small cell lung cancer should not be recommended for post-operative radiotherapy, according to results from the phase 3 LungART trial that were presented during the ESMO Virtual Congress 2020, due to nonstatistically significant increase in disease-free survival versus those treated in the control group.

Frontline Lorlatinib Leads to Better Outcomes Compared With Crizotinib in Advanced ALK+ NSCLC

September 20, 2020

According to results from the phase 3 CROWN trial, the third-generation ALK tyrosine kinase inhibitor loralitinib achieved a significant improvement in progression-free survival as well as higher overall and intracranial response rates, compared with crizotinib in patients with ALK-positive non–small cell lung cancer.

Despite High Post-Surgical Mortality, Promising Responses Observed With Neoadjuvant Durvalumab in NSCLC

September 19, 2020

The use of durvalumab as treatment of patients with resectable non–small cell lung cancer in the neoadjuvant setting showed preliminary promise with a satisfactory complete surgical resection rate, according to the phase 2 IFCT-1601 IONESC study.

Tumor Regression Is Observed With Neoadjuvant Atezolizumab in Resectable NSCLC

September 19, 2020

In patients with non–small cell lung cancer who were eligible for surgical resection, treatment with one dose of neoadjuvant atezolizumab was considered safe and induced major pathological responses in some patients.

Durability of Responses With Larotrectinib Demonstrated in TRK+ Lung Cancer Population

September 17, 2020

Larotrectinib induced durable responses in patients with TRK fusion–positive lung cancer, even in patients with central nervous system metastases, according to results pooled from 2 trials of the TRK inhibitor and presented in a poster at the European Society of Medical Oncology Virtual Congress 2020.

Previous Liver Infection Requires a Rapid and Flexible Treatment Response in NSCLC

September 16, 2020

Jorge A. Rios, MD, a medical oncologist at Zangmeister Cancer Center in Columbus, Ohio, part of the American Oncology Network, shared the case of a woman who developed multiple severe adverse events attributable to durvalumab.

Kim Evaluates Atezolizumab and Durvalumab for ES-SCLC

September 09, 2020

Edward Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute in Charlotte, NC, discussed the use of atezolizumab and durvalumab as treatment of a 73-year-old female patient with extensive-stage small cell lung cancer during a virtual Case Based Peer Perspective event.

A 58-Year-Old Woman With ALK+ Non–Small Cell Lung Cancer

September 08, 2020

Lyudmila Bazhenova, MD, presents the case of a 58-year-old woman with ALK+ non–small cell lung cancer.